First Tracks Biotherapeutics (NASDAQ:TRAX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $47.8750.

A number of brokerages have issued reports on TRAX. Barclays boosted their price target on shares of First Tracks Biotherapeutics from $40.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. Wells Fargo & Company increased their target price on shares of First Tracks Biotherapeutics from $30.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Wall Street Zen raised shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd. Leerink Partners initiated coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $46.00 price target for the company. Finally, Piper Sandler initiated coverage on First Tracks Biotherapeutics in a research note on Monday, May 4th. They issued an “overweight” rating and a $54.00 price objective on the stock.

First Tracks Biotherapeutics Trading Up 2.0%

TRAX opened at $46.95 on Thursday. The business’s 50-day moving average price is $26.32. First Tracks Biotherapeutics has a 12-month low of $14.72 and a 12-month high of $49.58. The firm has a market cap of $1.64 billion and a price-to-earnings ratio of -25.52.

First Tracks Biotherapeutics is a healthcare company in the Biotechnology industry.